|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2,200.00 - 2,265.00|
|52 Week Range||1,901.15 - 3,399.90|
|PE Ratio (TTM)||32.74|
|Earnings Date||Oct 23, 2017 - Oct 27, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||2,542.68|
Indivior said on Friday its U.S. subsidiary has filed patent lawsuits against firms seeking approval for generic versions of its opioid addiction treatment Suboxone, which generates 80 percent of Indivior's revenue. The lawsuits were filed against Dr. Reddy's, Allergan Plc's Actavis Laboratories, Endo International's Par Pharmaceutical, Alvogen Pharma US, Teva Pharmaceutical Industries and Mylan NV.
Aurigene Discovery Technologies Limited, a wholly owned subsidiary of Dr. Reddy’s Laboratories Ltd. and a specialized biotechnology company engaged in discovery and early clinical development of novel and best-in-class therapies to treat cancer and inflammatory diseases, today announced plans to initiate a Phase 2 trial of CA-170, a PDL1-VISTA inhibitor to be conducted at sites in India.
Dr. Reddy’s Laboratories Ltd. announced that the Company will be present at the Morgan Stanley 15th Annual Global Healthcare Conference on Tuesday, September 12th, 2017, in New York City.